CD20 may be a better target than CD19 anyway | PGEN Message Board Posts


PGEN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  45837 of 46453  at  9/26/2021 1:11:41 PM  by

clsm

The following message was updated on 9/26/2021 1:11:41 PM.

 In response to msg 45569 by  rubraquercus
view thread

Re: CD20 may be a better target than CD19 anyway

2seventy Bio, the planned oncology spin-off of BLUE, will file an IND in the next few months for bbT369. This is an auto CAR-T that targets CD20 and CD79a, has split CD28 and 4-BB co-stim domains, and CBL-B knockout [1,2].

Also, a second IND will be for DARIC33. This is another auto CAR-T, but targets CD33, is under the control of rapamycin [3] and will be tested in both adult and paediatric patients. A next-gen version will target a second antigen and be enhanced (both undisclosed).

Refs:
1 https://ashpublications.org/blood/article/132/Supplement 1/338/264550/Knockout-of-CBLB-Greatly-Enhances-Anti-Tumor
2 https://jitc.bmj.com/content/9/1/e001688
3 https://insight.jci.org/articles/view/124430


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...